Catastrophic Cardiac Events During Transcatheter Aortic Valve Replacement.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
10 2021
Historique:
received: 20 11 2020
revised: 03 05 2021
accepted: 05 05 2021
pubmed: 17 5 2021
medline: 28 12 2021
entrez: 16 5 2021
Statut: ppublish

Résumé

Perioperative complications of transcatheter aortic valve replacement (TAVR) are decreasing but can be catastrophic when they occur. Systematic reports of the nature of these events are lacking in the contemporary era. Our study aimed to report the incidence, outcomes, and perioperative management of catastrophic cardiac events in patients undergoing TAVR and to propose a working strategy to address these complications. This is a retrospective cohort study of patients who developed catastrophic cardiac events during or immediately after TAVR between 2015 and 2019 at a single academic centre. Of 2102 patients who underwent TAVR, 51 (2.5%) developed catastrophic cardiac events. The causes included cardiac perforation and tamponade (n = 19, 37.3%), acute left- ventricular failure (n = 10, 19.6%), coronary artery obstruction (n = 10, 19.6%), aortic-root disruption (n = 7, 13.7%), and device embolization (n = 5, 9.8%). Twenty-four patients (47.0%) with catastrophic cardiac events required stabilization by either intra-aortic balloon counter-pulsation or extracorporeal membrane oxygenation. The in-hospital mortality rate increased by 11.7-fold for patients with catastrophic cardiac events compared with those without (25.5% vs 2.0%, P < 0.001). Patients who developed aortic root disruption had the highest mortality rate (42.8%) compared with the others. The incidence of catastrophic cardiac events remained stable over a 5-year period, but the associated mortality decreased from 38.5% in 2015 to 9.1% in 2019. Catastrophic cardiac events during TAVR are rare, but they account for a dramatic increase in perioperative mortality. Early recognition and development of a standardized perioperative team approach can help manage patients experiencing these complications.

Sections du résumé

BACKGROUND
Perioperative complications of transcatheter aortic valve replacement (TAVR) are decreasing but can be catastrophic when they occur. Systematic reports of the nature of these events are lacking in the contemporary era. Our study aimed to report the incidence, outcomes, and perioperative management of catastrophic cardiac events in patients undergoing TAVR and to propose a working strategy to address these complications.
METHODS
This is a retrospective cohort study of patients who developed catastrophic cardiac events during or immediately after TAVR between 2015 and 2019 at a single academic centre.
RESULTS
Of 2102 patients who underwent TAVR, 51 (2.5%) developed catastrophic cardiac events. The causes included cardiac perforation and tamponade (n = 19, 37.3%), acute left- ventricular failure (n = 10, 19.6%), coronary artery obstruction (n = 10, 19.6%), aortic-root disruption (n = 7, 13.7%), and device embolization (n = 5, 9.8%). Twenty-four patients (47.0%) with catastrophic cardiac events required stabilization by either intra-aortic balloon counter-pulsation or extracorporeal membrane oxygenation. The in-hospital mortality rate increased by 11.7-fold for patients with catastrophic cardiac events compared with those without (25.5% vs 2.0%, P < 0.001). Patients who developed aortic root disruption had the highest mortality rate (42.8%) compared with the others. The incidence of catastrophic cardiac events remained stable over a 5-year period, but the associated mortality decreased from 38.5% in 2015 to 9.1% in 2019.
CONCLUSIONS
Catastrophic cardiac events during TAVR are rare, but they account for a dramatic increase in perioperative mortality. Early recognition and development of a standardized perioperative team approach can help manage patients experiencing these complications.

Identifiants

pubmed: 33992736
pii: S0828-282X(21)00246-4
doi: 10.1016/j.cjca.2021.05.002
pmc: PMC8590698
mid: NIHMS1744747
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1522-1529

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK109574
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK122796
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL133900
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL154720
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Yafen Liang (Y)

Department of Anesthesiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. Electronic address: yafen.liang@uth.tmc.edu.

Abhijeet Dhoble (A)

Department of Cardiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA.

Adarsh Pakanati (A)

Department of Anesthesiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA.

Yelin Zhao (Y)

Department of Cardiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA.

Felix Kork (F)

Department of Anesthesiology, Medical Faculty, RWTH Aachen University, Aachen, Germany.

Wei Ruan (W)

Department of Anesthesiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA.

Travis Markham (T)

Department of Anesthesiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA.

Richard Smalling (R)

Department of Cardiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA.

Prakash Balan (P)

Department of Cardiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA.

Anthony Estrera (A)

Department of Cardiac Surgery, The University of Texas Health Science Center at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA.

Tom C Nguyen (TC)

Department of Cardiac Surgery, The University of Texas Health Science Center at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA.

Igor Gregoric (I)

Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA.

Biswajit Kar (B)

Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA.

Holger Eltzschig (H)

Department of Anesthesiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH